Xhance (fluticasone propionate) is a prescription nasal spray. It’s used to treat nasal and sinus inflammation with or without nasal polyps in adults. This drug can interact with other ...

YARDLEY, PA — Optinose (NASDAQ: OPTN) has announced preliminary unaudited net product revenue of $22.4 million for the fourth ...

In light of these financial results, OptiNose revised its 2024 sales forecast for Xhance, its nasal spray treatment, to a range of $75 million to $79 million. Despite this adjustment, the company ...

In light of these financial results, OptiNose revised its 2024 sales forecast for Xhance, its nasal spray treatment, to a range of $75 million to $79 million. Despite this adjustment, the company ...

(RTTNews) - Optinose, Inc. (OPTN), a pharmaceutical company focused on ear, nose and throat or ENT and allergy, announced Wednesday preliminary XHANCE (fluticasone propionate) net product revenue ...